Tranexamic acid

• Description:

  Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis. Tranexamic acid is a PROTAC linker. Tranexamic acid is used to synthesize PROTACs (e.g. LZ-07 (HY-172590) ) [1][2][3][4][5][6].

• Product Name Alternative:

  Cyclocapron

• UNSPSC:

  12352211

• Hazard Statement:

  H315, H319, H335

• Target:

  AMPK; IGF-1R; Mitophagy; MMP; PROTAC Linkers

• Type:

  Reference compound

• Related Pathways:

  Autophagy; Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; PROTAC; Protein Tyrosine Kinase/RTK

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Tranexamic-acid.html

• Purity:

  99.88

• Solubility:

  DMSO : < 1 mg/mL|H2O : 50 mg/mL (ultrasonic)

• Smiles:

  O=C ([C@H]1CC[C@H] (CN) CC1) O

• Molecular Formula:

  C8H15NO2

• Molecular Weight:

  157.21

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Prudovsky I, et al. Tranexamic acid suppresses the release of mitochondrial DNA, protects the endothelial monolayer and enhances oxidative phosphorylation [J]. Journal of cellular physiology, 2019, 234 (11) : 19121-19129.|[2]Wu G, et al. Tranexamic acid is an active site inhibitor of urokinase plasminogen activator [J]. Blood advances, 2019, 3 (5) : 729-733.|[3]Draxler D F, et al. Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis [J]. Journal of Thrombosis and Haemostasis, 2019, 17 (12) : 2174-2187.|[4]Hiramoto K, et al. The amelioration effect of tranexamic acid in wrinkles induced by skin dryness [J]. Biomedicine & Pharmacotherapy, 2016, 80: 16-22.|[5]Sindet-Pedersen S, et al. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery [J]. New England Journal of Medicine, 1989, 320 (13) : 840-843.|[6]Zhen Li, et al., Developing potent anti-inflammatory IRAK4-targeting PROTACs with simplified CRBN ligands, Chinese Chemical Letters, 2025, 111033, ISSN 1001-8417.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  MMP-1

• CAS Number:

  1197-18-8